Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)

Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) Muhammad Ali Khalid Thu, June 11, 2026 at 12:20 PM GMT+2 2 min read CORT Corcept Therapeutics Inc. (NASDAQ: CORT ) is one of the 10 best AI driven biotech stocks to invest in . On June 8, Corcept Therapeutics Inc.

(NASDAQ:CORT) revealed the latest data from Catalyst and Momentum trials during the American Diabetes Association’s 86th Scientific Sessions. The results show a crucial role of hypercortisolism in type 2 diabetes, which appears to be difficult to contain. Moreover, it also extends influence on resistant hypertension.

Image Point Fr/Shutterstock. com The data also indicated the potential of the cortisol modulation procedure. The company’s Chief Development Officer, Bill Guyer, expanded on the data by emphasizing that hypercortisolism seems to be a major driver of cardiometabolic conditions.

He stated: “Data consistently show that hypercortisolism is an underlying driver of treatment resistant cardiometabolic disease, including in patients receiving best-in-class therapies like GLP-1s. Data from CATALYST demonstrate that treatment with a cortisol modulator, such as Korlym, can be synergistic with GLP-1s or tirzepatide to help patients better control type 2 diabetes. It is our hope that this new research will lead to increased screening for hypercortisolism and improved treatment.

” Back on May 28, Canaccord Genuity increased its target price for Corcept Therapeutics Inc. (NASDAQ:CORT) from $110 to $135, which represents an adjusted upside potential of almost 77%. The firm reiterated a Buy rating on the stock.

Genuity attributed the revision to the company’s surprise announcement, where they intend to resubmit the NDA relating to relacorilant, which will be utilized to cure patients with hypercortisolism. Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage pharmaceutical company that is involved in developing therapies for severe conditions.

These include endocrinologic, oncologic, metabolic, and neurologic disorders. It is developing medicines that target hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.

If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock . READ NEXT:  33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years . Disclosure: None.

Follow Insider Monkey on Google News .